Literature DB >> 28357685

Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary.

Attila Péter Király1, Krisztián Kállay2, Ambrus Gángó1, Ádám Kellner3, Miklós Egyed3, Anita Szőke4, Richárd Kiss1, István Vályi-Nagy5, Judit Csomor1, András Matolcsy1, Csaba Bödör6.   

Abstract

Although genetic predisposition to haematological malignancies has long been known, genetic testing is not yet the part of the routine diagnostics. In the last ten years, next generation sequencing based studies identified novel germline mutations in the background of familial aggregation of certain haematologic disorders including myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). This is supported by the fact that the myeloid neoplasms with genetic predisposition represent a new category in the revised 2016 World Health Organization classification. According to the new classification, these disorders are subdivided based on the clinical and genetic features, including myeloid neoplasms with germline predisposition alone, or with pre-existing platelet disorder, cytopaenias or other organ failures. The predisposing genetic factors include mutations in the RUNX1, CEBPA, GATA2, ANKRD26, ETV6, DDX41, TERC or TERT and SRP72 genes. The genes affected in these syndromes are important regulators of haemopoiesis and are frequently implicated in leukaemogenesis, providing deeper insight into the understanding of normal and malignant haemopoiesis. Despite the growing knowledge of germline predisposing events in the background of familial myeloid malignancies, the germline genetic component is still unknown in a subset of these pedigrees. Here, we present the first study of inherited myeloid malignancies in Hungary. We identified three families with apparent clustering of myeloid malignancies with nine affected individuals across these pedigrees. All tested individuals were negative for CEBPA, GATA2, RUNX1, ANKRD26, ETV6, DDX41, TERC or TERT and SRP72 mutations, suggesting the presence of so far unidentified predisposing mutations.

Entities:  

Keywords:  Familial MDS/AML; Genetic predisposition; Germline mutation

Mesh:

Substances:

Year:  2017        PMID: 28357685     DOI: 10.1007/s12253-017-0216-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  33 in total

1.  Targeted next-generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia.

Authors:  Karl Haslam; Stephen E Langabeer; Amjad Hayat; Eibhlin Conneally; Elisabeth Vandenberghe
Journal:  Br J Haematol       Date:  2015-11-03       Impact factor: 6.998

2.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

3.  How I diagnose and manage individuals at risk for inherited myeloid malignancies.

Authors: 
Journal:  Blood       Date:  2016-07-28       Impact factor: 22.113

Review 4.  Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists.

Authors:  Nicolas Duployez; Sophie Lejeune; Aline Renneville; Claude Preudhomme
Journal:  Expert Rev Hematol       Date:  2016-11-21       Impact factor: 2.929

5.  Mutation of CEBPA in familial acute myeloid leukemia.

Authors:  Matthew L Smith; Jamie D Cavenagh; T Andrew Lister; Jude Fitzgibbon
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).

Authors:  Claude Preudhomme; Christophe Sagot; Nicolas Boissel; Jean-Michel Cayuela; Isabelle Tigaud; Stéphane de Botton; Xavier Thomas; Emmanuel Raffoux; Charlotte Lamandin; Sylvie Castaigne; Pierre Fenaux; Hervé Dombret
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

8.  GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.

Authors:  Claire L Green; Kiran Tawana; Robert K Hills; Csaba Bödör; Jude Fitzgibbon; Sarah Inglott; Phil Ancliff; Alan K Burnett; David C Linch; Rosemary E Gale
Journal:  Br J Haematol       Date:  2013-04-05       Impact factor: 6.998

9.  Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency.

Authors:  Rachel Emma Dickinson; Helen Griffin; Venetia Bigley; Louise N Reynard; Rafiqul Hussain; Muzlifah Haniffa; Jeremy H Lakey; Thahira Rahman; Xiao-Nong Wang; Naomi McGovern; Sarah Pagan; Sharon Cookson; David McDonald; Ignatius Chua; Jonathan Wallis; Andrew Cant; Michael Wright; Bernard Keavney; Patrick F Chinnery; John Loughlin; Sophie Hambleton; Mauro Santibanez-Koref; Matthew Collin
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

10.  Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Christopher N Hahn; Chan-Eng Chong; Catherine L Carmichael; Ella J Wilkins; Peter J Brautigan; Xiao-Chun Li; Milena Babic; Ming Lin; Amandine Carmagnac; Young K Lee; Chung H Kok; Lucia Gagliardi; Kathryn L Friend; Paul G Ekert; Carolyn M Butcher; Anna L Brown; Ian D Lewis; L Bik To; Andrew E Timms; Jan Storek; Sarah Moore; Meryl Altree; Robert Escher; Peter G Bardy; Graeme K Suthers; Richard J D'Andrea; Marshall S Horwitz; Hamish S Scott
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

View more
  3 in total

Review 1.  Spliceosomal factor mutations and mis-splicing in MDS.

Authors:  Courtney E Hershberger; Noah J Daniels; Richard A Padgett
Journal:  Best Pract Res Clin Haematol       Date:  2020-08-01       Impact factor: 3.020

Review 2.  Unique role of DDX41, a DEAD-box type RNA helicase, in hematopoiesis and leukemogenesis.

Authors:  Satoru Shinriki; Hirotaka Matsui
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

Review 3.  Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data.

Authors:  Ziqi Wan; Bing Han
Journal:  Ther Adv Hematol       Date:  2021-07-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.